Acadia Claims Success For Nuplazid In A Broader Psychosis Indication

The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.

Business success concept with target as motivation (3D Rendering) - Illustration — Acadia's pimavanserin trial was stopped early due to efficacy in dementia-related psychosis

Acadia Pharmaceuticals Inc. is on track to file for US Food and Drug Administration approval for a potential new indication for Nuplazid (pimavanserin) for the treatment of dementia-related psychosis sometime in 2020. The company announced on 9 September that a Phase III trial testing pimavanserin in the patient population will be stopped early based on a positive interim efficacy analysis.

The early good news surprised investors, with the company's stock jumping 75% to open the day at $41.75. Some investors...